Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

DUBLIN — September 18, 2018 — Medtronic plc (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a single-arm study to evaluate the CoreValve Evolut(TM)TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality.

First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System and Enrolls in Post-Market Registry

FLAGSTAFF, Ariz. (SEPTEMBER 17, 2018) — W. L. Gore & Associates, Inc. (Gore) today announced the first European patient implant of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System. This next-generation endovascular aneurysm repair (EVAR) device is indicated to treat the broadest range of abdominal aortic aneurysms (AAA) in patients with challenging anatomies.

Racial, socioeconomic disparities in outcomes ‘systemic,’ not hospital-based

Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities 

Despite overall advances in healthcare and targeted initiatives to address disparities in care, black patients and those with lower socioeconomic status tend to have worse outcomes for a range of conditions in the U.S. However, based on a recent analysis published in JAMA Network Open, hospital-level differences don’t explain the phenomenon.